Oxam¯atin [(2E) -5 -[3 -[(phenylsufonyl) amino] phenyl]-pent-2-en-4-ynohydroxamic acid] induces transcriptional activation of junD and morphological reversion in various NIH3T3-derived transformed cell lines. We found that oxam¯atin showed in vitro antiproliferative activity against various mouse and human tumor cell lines with drastic changes in the cell morphology and in vivo antitumor activity against B16 melanoma. Oxam¯atin caused an elongated cell shape with ®lamentous protrusions as well as arrest of the cell cycle at the G1 phase in HeLa cells. These phenotypic changes of HeLa cells were apparently similar to those by trichostatin A (TSA), a speci®c inhibitor of histone deacetylase (HDAC). The eect of oxam¯atin on the transcriptional activity of the cytomegalovirus (CMV) promoter was examined and compared with known HDAC inhibitors, TSA, sodium n-butyrate, and FR901228. Oxam¯atin as well as all these inhibitors greatly enhanced the transcriptional activity of the CMV promoter in a dose-dependent manner. Oxam¯atin, like TSA, inhibited intracellular HDAC activity, as a result of which marked amounts of acetylated histone species accumulated. Finally, eects on expression of several endogenous genes involved in cell morphology and cell cycle control in HeLa cells were analysed. Expression of gelsolin, cyclin E and Cdk inhibitors including p21 WAF1/Cip1 was highly augmented, while that of cyclin A and cyclin D1 was decreased by oxam¯atin. These results suggest that changes in the expression pattern of the genes regulating cell morphology and the cell cycle due to histone hyperacetylation are responsible for the antitumor activity, the morphological change and the cell cycle arrest induced by oxam¯atin.
Introduction
Several natural and synthetic compounds have been isolated by screening for detransforming activity using oncogene-transformed cells. For instance, trichostatin A (TSA), trapoxin, and FR901228 revert the cell morphology of v-sis and v-ras-transformed cells to apparently normal ones (Futamura et al., 1995; Itazaki et al., 1990; Sugita et al., 1992; Ueda et al., 1994b) . Histone deacetylases (HDAC) were shown to be the molecular targets of these agents (Kijima et al., 1993; Nakajima et al., 1998; Yoshida et al., 1990) . Human HDAC (HDAC1) was puri®ed and cloned by using trapoxin-based anity matrix (Taunton et al., 1996) . Accumulating evidence suggests that histone acetylation and deacetylation play important roles in the regulation of transcription in eukaryotic cells (Grunstein, 1997; Pazin and Kadonaga, 1997; Wade et al., 1997; Wole, 1996) . It has been proposed that the neutralization by acetylation of the positive charge of lysine residues in the N-terminal tails of core histones leads to loosening histone-DNA contacts, which facilitates the accessibility of a variety of factors to DNA. Although the mechanism by which the HDAC inhibitors induce suppression of oncogene-mediated transformation is still unclear, it seems likely that the inhibitors release the HDAC-mediated transcriptional repression of tumor suppressor genes.
Aromatic sulfonamides are widely used as chemically and biologically stable pharmacophores for synthesizing a variety of biologically active compounds such as protein kinase inhibitors (Inagaki et al., 1985) , carbonic anhydrase inhibitors (Supuran et al., 1997) , and metalloproteinase inhibitors (Tamura et al., 1998) . Oxam¯atin ( Figure 1 ) is such an aromatic sulfonamide derivative with a hydroxamic acid group that was recently identi®ed as a compound inducing the morphological reversion of v-K-ras-transformed NIH3T3 cells from a chemical library (Sonoda et al., 1996) . In addition, the morphology of NIH3T3 cells transformed by various other oncogenes such as v-sis, v-src, MEK EE or v-fos was also reverted by oxam¯atin. Oxam¯atin was found to induce the expression of a transcription factor Jun D and an extracellular matrix protein ®bronectin. Since the cyclic AMP-responsive element (CRE) in the promoter of the ®bronectin gene was required for the transcriptional activation by oxam¯atin, it is hypothesized that the overproduction of Jun D enhances the ®bronectin expression via CRE and competes for AP-1 sites of other growth-associated genes with c-Jun (Sonoda et al., 1996) , an oncogenic transcription factor involved in Ras-mediated transformation (Chen et al., 1995) . However, the exact target molecule of oxam¯atin is still unknown.
Here we show that oxam¯atin induces a morphological change of HeLa cells similar to that induced by HDAC inhibitors like TSA, and indeed inhibits HDAC in vivo and in vitro. Upon treatment, the expression levels of several endogenous and exogenous genes were dramatically changed, probably due to the induced histone hyperacetylation. Among these, gelsolin and Cdk inhibitors such as p21 WAF1/Cip1 were highly up-regulated by oxam¯atin. Furthermore, we demonstrated in vivo and in vitro antitumor activity of oxam¯atin. These results suggest that oxam¯atin, a new HDAC inhibitor, causes morphological reversion and cell cycle arrest of tumor cells by changing the pattern of gene expression and has potential as therapeutics for a treatment of cancer.
Results

Antiproliferative activity of oxam¯atin
Oxam¯atin selectively suppresses anchorage-independent growth of NIH3T3 cells transformed by v-K-ras, v-src, MEK EE or v-fos compared to their anchoragedependent growth of the parental cells (Sonoda et al., 1996) . We analysed the eect of oxam¯atin on the proliferation of mouse and human tumor cell lines.The antiproliferative activity against the cell lines was determined by the MTT assay (Table 1) . Fifty per cent inhibitory concentrations of oxam¯atin for all the cell lines except CCD-19Lu, a normal human lung cell line, were below 0.72 mg/ml, while that for CCD-19Lu was 1.4 mg/ml. Proliferation of both parental and adriamycin-resistant P388 mouse leukemia was similarly inhibited by oxam¯atin, suggesting that oxamatin is not a substrate for P-glycoprotein. During these experiments, we found that cell morphology of adherent cell lines such as HeLa was signi®cantly changed.
To test whether oxam¯atin inhibits cell cycle progression, we treated HeLa cells with various concentrations of oxam¯atin for 24 h and determined the proportion of S phase cells by measuring BrdU incorporation. As shown in Figure 2a , the BrdU incorporation was reduced in a dose-dependent manner, and was almost completely inhibited at the concentrations higher than 0.5 mg/ml. We further analysed the eect of oxam¯atin on the cell cycle of HeLa cells by¯ow cytometry. The nuclei isolated from the cells that had been treated with 1 mg/ml oxam¯atin for 0, 12 and 24 h were stained with propidium iodide, and their DNA contents were measured. An asynchronous culture of HeLa cells at time 0 showed approximately 40% of G0/G1 phase cells, 40% of S phase cells, and 20% of G2/M phase cells in their population (Figure 2b) . However, the number of the cells in S phase markedly decreased to about 5% of the total cell number 12 h after the oxam¯atin treatment. In contrast, the number of cells in G0/G1 phase increased almost twofold within 24 h. These results indicate that oxam¯atin caused arrest mainly at the G1 phase in HeLa cells.
Eects of oxam¯atin on the cell morphology of HeLa cells
During the experiments of in vitro cytotoxicity described above, we found that oxam¯atin induced the morphological changes of human cell lines characteristic of cells treated with TSA and other HDAC inhibitors (Hoshikawa et al., 1994) . Figure 3 shows the morphological changes of HeLa cells treated with oxam¯atin as well as TSA. HeLa cells are normally oval or polygonal, with few cells showing elongation. However, treatment with 0.1 mg/ml of oxam¯atin for 24 h caused a marked increase in the cells with ®lamentous protrusions. Moreover, almost all the cells showed a characteristic elongated cell shape when treated with more than 0.5 mg/ml (Figure 3a ). These morphological changes were apparently similar to those of TSA-treated cells (Figure 3a) . The morphological changes induced by TSA required de novo transcription and translation (Hoshikawa et al., 1994) . We therefore examined whether protein and RNA synthesis inhibitors aect the oxam¯atin-induced morphological changes (Figure 3b ). Simultaneous addition of cycloheximide or actinomycin D with oxam¯atin almost completely abolished the activity of oxam¯atin to induce the morphological changes of HeLa cells. These results suggest that oxam¯atin induces the morphological changes through de novo protein and RNA syntheses as does TSA.
Eects of oxam¯atin on the integrated CMV promoter activity n-Butyrate and TSA are known to modulate transcriptional regulatory elements, including viral elements such as retroviral long terminal repeats (Chen et al., 1997) , simian virus (Goldberg et al., 1992; Nakajima et al., 1998) and cytomegalovirus promoters (Dion et al., 1997; Tanaka et al., 1991) . To analyse the eect of oxam¯atin on the activity of modulating the integrated viral promoters, we determined the luciferase reporter activity in NIH3T3 cells stably transfected with pBCLuc. n-Butyrate, TSA and FR901228 enhanced the CMV promoter activity, reaching 12-, 18-and 50-fold induction, respectively, at each highest concentration tested. Oxam¯atin was also found to stimulate the promoter activity in a dose-dependent manner, and about a 40-fold increase was observed at the concentration of 2.0 mg/ml (data not shown).
Oxam¯atin inhibits HDAC
Similarity of the phenotypes of mammalian cells caused by oxam¯atin to those by other HDAC inhibitors suggested that their target sites might be related. In addition, oxam¯atin possesses an aromatic sulfonamide group and an acylhydroxamic acid group, the latter of which is structurally similar to TSA (Figure 1 ). Since TSA causes hyperacetylation of histones by inhibiting HDAC, we examined the level of histone acetylation in oxam¯atin-treated cells by acid/urea/Triton (AUT) gel electrophoresis. AUT gel electrophoresis allows separation of each cellular histone (H1, H2A, H2B, H3 and H4) with dierent extents of acetylation, due to slower migration of the acetylated species. Figure 4a shows the pro®les of histones extracted from oxam¯atin-or TSA-treated HeLa cells. Oxam¯atin apparently induced the accumulation of highly acetylated histones, characterized by decreases in the most rapid migration bands of each histone species and the appearance of additional slower ones like a ladder on the AUT gel. The level of acetylation of core histones is the result of equilibrium between activities of the two families of enzymes: histone acetyltransferases (HAT) and HDAC.
To determine whether the induced histone hyperacety- 6 HeLa cells were cultured for 24 h and 1 mg/ml of oxam¯atin was added to the culture at time 0 h. After incubation for the indicated time, cells were collected and their isolated nuclei were analysed by¯ow cytometry. Distribution of cells in cell cycle was determined using a ModFit LT software lation is due to increased acetylation or decreased deacetylation, we tested whether oxam¯atin directly inhibits HDAC partially puri®ed from mouse FM3A cells. As shown in Figure 4b , oxam¯atin at low concentrations inhibited HDAC activity in a dosedependent manner. The IC 50 value of oxam¯atin for the enzyme preparation was determined to be 15.7 nM, which was slightly higher than that of TSA (Table 2 ).
These results indicate that oxam¯atin is a novel sulfonamide derivative with HDAC inhibitory activity.
Eects of oxam¯atin on endogenous gene expression
All known HDAC inhibitors in addition to oxam¯atin induce G1 cell cycle arrest and morphological changes in various cell lines (Fallon and Cox, 1979; Kijima et , 1993; Nakajima et al., 1998; Yoshida and Beppu, 1988) . Recent studies have shown that HAT acts as the transcriptional coactivator (Bannister and Kouzarides, 1996; Brownell et al., 1996; Mizzen et al., 1996; Ogryzko et al., 1996; Yang et al., 1996b) whereas HDAC behaves as the corepressor Hassig et al., 1997; Kadosh and Struhl, 1997; Laherty et al., 1997; Nagy et al., 1997; Yang et al., 1996a) . Therefore, it seems reasonable that HDAC inhibitors exhibit various biological activities by directly aecting the transcription of some endogenous genes. In fact, induction of Jun D expression by oxam¯atin was reported previously (Sonoda et al., 1996) . We analysed the expression of several endogenous genes mainly related to cell cycle control by RT ± PCR (data not shown) or Western blotting ( Figure 5 ). Both mRNA and the protein levels of Cdc2, Cdk2, Cdk4, and Cdk6 were unchanged upon treatment of HeLa cells with 1 mg/ml of oxam¯atin for 24 h (data not shown). On the other hand, gelsolin, cyclin E and three Cdk inhibitors in addition to Jun D were obviously upregulated ( Figure 5 ). In contrast, cyclins A and D1 were markedly down-regulated in a dose-dependent manner. Interestingly, the dose response of p27
Kip1 was dierent from those of other Cdk inhibitors: it increased to the maximum level at 0.5 mg/ml but decreased as the concentration increased to 2 mg/ml.
Signi®cant increases in gelsolin, p21
Waf1/Cip1 and cyclin E , p27
Kip1 and p16
as well as a decrease in cyclin A coincided well with reduction of the number of S phase cells (Figure 2a ). Essentially the same expression pattern was observed for the cells treated with TSA (Kim et al., unpublished data). These results suggest that the drastic changes in the intracellular protein levels of these important regulators for the cell cycle and cell morphology are associated with the cell cycle arrest and morphological changes caused by HDAC inhibitors.
Antitumor activity of oxam¯atin
The above results suggest a pharmaceutical potential of oxam¯atin against cancer. To investigate the in vivo antitumor activity of oxam¯atin, we measured the increase in the life span (ILS) of mice transplanted with B16 murine melanoma upon treatment with oxamatin. The cell suspension of B16 melanoma was inoculated into the peritoneum of BDF1 mice and oxam¯atin was injected intraperitoneally six times on day 1, 3, 5, 7, 9 and 11 after inoculation at the dose of 8 ± 50 mg/kg. The days of survival were then counted and the ILS% was calculated (Table 3) . Injection of oxam¯atin, six times at the dose of 20 mg/kg, exhibited a signi®cant increase in the days of survival (38% of ILS). The ILS of the mice treated with oxam¯atin at the dose of 50 mg/kg was calculated to be more than 67% and one mouse survived over 60 days after tumor inoculation. No subsidiary eect, such as body weight loss, was observed at least up to this dose.
Discussion
Oxam¯atin is an aromatic sulfonamide derivative with a hydroxamic acid group that induces morphological reversion in various NIH3T3-derived cell lines transformed with oncogenes such as v-ras, v-sis, v-src, MEK EE or v-fos. Although previous studies suggested that the morphological changes were caused by activation of Jun D and subsequent ®bronectin gene expression through the cAMP responsive element (Sonoda et al., 1996) , the molecular mechanism of the action of oxam¯atin still remained unclear. In this study, we demonstrated that oxam¯atin was a novel inhibitor of mammalian HDAC. Oxam¯atin was much stronger in inhibiting HDAC than n-butyrate (Cousens et al., 1979) and depudecin (Kwon et al., 1998) , but the IC 50 value was slightly higher than those of other known inhibitors (Table 2 ). To date, there are several dierent classes of HDAC inhibitors. Oxam¯atin belongs to the class of acylhydroxamic acids like TSA (Figure 1 ). The mechanism of HDAC inhibition by oxam¯atin may therefore be related to that of TSA. Each of these compounds has an acylic chain with a hydroxamic acid group presumed to mimic the side chain of an e-N-acetylated lysine residue. It has recently been proposed that HDAC phylogenically belongs to the enzymes required for metal ions for their activity (Khochbin and . The hydroxamate moiety is likely to interact with key catalytic elements such as His141 of HDAC1 in the enzyme active sites as a ligand of a catalytic metal ion.
All HDAC inhibitors so far identi®ed cause cell cycle arrests at G1 in various cell lines (Yoshida et al., 1995) . We showed that oxam¯atin also inhibits cell cycle progression in HeLa cells. However, the mechanism by which HDAC inhibitors induce cell cycle arrest is still unknown. Recent identi®cation and functional analyses of human HATs and HDACs demonstrated that HAT is recruited to promoter regions of genes by transcriptional activators while HDAC is targeted to DNA regions by association with transcriptional repressors, thereby leading to transcriptional activation and repression, respectively (Grunstein, 1997; Pazin and Kadonaga, 1997; Wade et al., 1997; Wole, 1996) . It is therefore likely that HDAC inhibitors directly aect the transcriptional activity of a certain class of genes. We searched for the genes of which transcription was largely aected by oxam¯atin, and found that gelsolin, cyclin E and three dierent Cdk inhibitors were elevated while cyclins D1 and A were reduced. During the G0 to S transition, Cdkcyclin complexes are sequentially activated: Cdk4-or Cdk6-cyclin D in early to mid G1, Cdk2-cyclin E in mid-to late G1 and Cdk2-cyclin A in late G1 to early S (Sherr, 1993) . Active Cdks are presumed to phosphorylate regulatory proteins such as the retinoblastoma tumor suppressor protein (Rb), thereby triggering events that are essential for G1 progression (Goldberg et al., 1992) . The kinase activity of Cdks is regulated by not only association with G1 cyclins but also a family of Cdk inhibitors such as p21 WAF1/Cip1 and p27 Kip1 (Sherr, 1994) . Oxam¯atin induced expression of these Cdk inhibitors and reduced cyclins D1 and A ( Figure 5 ), which may result in suppression of the kinase activity of Cdks. Among the Cdk inhibitors induced by oxam¯atin, dose response of the increase in the amount of p21 WAF1/Cip1 was best correlated with the decrease in S phase cells, suggesting that repression of the p21 WAF1/Cip1 gene contributes much to oxam¯atin-induced G1 arrest.
Oxam¯atin induces morphological reversion of various transformed cells as well as drastic morphological changes of HeLa cells. We showed that de novo protein synthesis is required for the morphological changes of HeLa cells (Figure 3b ). We previously showed that TSA caused enhanced expression of gelsolin, an actin regulatory protein (Hoshikawa et al., 1994) . In this study, we also showed that oxam¯atin caused a marked increase in gelsolin. Gelsolin, a protein which is highly conserved in vertebrates, controls the length of actin ®laments in vitro and the cell shape and motility in vivo by a variety of mechanisms (Cunningham et al., 1991) . A signi®cant decrease in the amount of gelsolin is associated with malignant transformation (Chaponnier and Gabbiani, 1989; Moriya et al., 1994; Porter et al., 1993; Vandekerckhove et al., 1990) . Gelsolin is one of the most strikingly down-regulated markers of the (Tanaka et al., 1995) . Moreover, a mutation of gelsolin at His321 or overproduction of wild-type gelsolin has been shown to induce morphological reversion and marked reduction of in vitro colony-forming activity as well as in vivo tumor incidence (MuÈ llauer et al., 1993) . Kothakota et al. (1997) reported that activation of actin-severing activity of gelsolin by caspase-3-mediated cleavage is responsible for morphological change in apoptosis. All of these observations strongly suggest that gelsolin plays important roles in regulating cell morphology upon both cell proliferation and apoptosis. Recently, gelsolin expression was suggested to be involved in morphological reversion of transformed cells by radicicol (Kwon et al., 1997) . It is therefore possible that the increased expression of gelsolin is associated with the drastic changes in the cell morphology upon treatment of HDAC inhibitors. Although in vivo treatment of cells with HDAC inhibitors induce histone hyperacetylation in most of chromatin regions, the number of genes of which transcription is in¯uenced is limited. Dierential display analysis demonstrated that only eight out of 340 genes were aected by TSA, indicating that more than 97% of genes are unaected by histone hyperacetylation (Van Lint et al., 1996) . It is currently unclear why a small subset of genes are speci®cally induced by HDAC inhibitors. In the present study, we showed that endogenous cyclin E expression was enhanced by oxam¯atin. Recently, it was shown that Rb represses the E2F-regulated promoter activity by recruiting HDAC (Brehm et al., 1998; Magnaghi et al., 1998) . Since cyclin E expression is regulated by E2F, inhibition of HDAC by oxam¯atin may relieve the repression by the Rb/HDAC complex targeted on the E2F site in the cyclin E promoter. Although the p21 WAF1/Cip1 gene promoter has E2F sites, E2F appears not to be involved in the speci®c induction by HDAC inhibitors. Sodium n-butyrate, a weak inhibitor of HDAC, was also reported to enhance the expression of p21 WAF1/Cip1 (Sowa et al., 1997) . Analysis of the p21 WAF1/Cip1 gene promoter suggested that the Sp1 sites but not the E2F sites were responsible for the butyrateinduced expression. It is obviously important to clarify the mechanism by which HDAC inhibitors enhance the expression of p21 WAF1/Cip1 . The activity of HDAC inhibitors to enhance expression of Cdk inhibitors or gelsolin may have some relevance to their clinical use. Chemical induction of p21 WAF1/Cip1 or gelsolin may compensate for the functional loss of the tumor suppressor gene product p16MTS1/INK4A, another Cdk inhibitor (Kamb et al., 1994a,b; Nobori et al., 1994) , or down-regulation of gelsolin in tumor cells. Accumulating evidence suggests a genetic link between histone acetylation and tumorigenesis. A genetic defect in one of the two copies of human CBP gene is associated with Rubinstein-Taybi syndrome which is accompanied by high malignancy (Petrij et al., 1995) . BRCA2, a breast cancer suppressor protein, was recently found to have HAT activity (Siddique et al., 1998) . These ®ndings suggest that some HAT genes act as tumor suppressors while some HDAC genes may act oppositely. In fact, oxam¯atin showed antitumor activity against B16 melanoma. FR901228, which was recently identi®ed as a new type of HDAC inhibitor (Nakajima et al., 1998) , is remarkably active in vivo against experimental tumors (Ueda et al., 1994a) and is now under clinical investigation (Phase I) in the National Cancer Institute (Bethesda, MD, USA). It is therefore useful in cancer chemotherapy to explore the possibility of oxam¯atin and other HDAC inhibitors.
Materials and methods
Cells and culture conditions
A mouse mammary gland tumor cell line, FM3A was cultured in ES medium (Nissui Pharmaceutical Co. Ltd., Tokyo, Japan) supplemented with 2% fetal bovine serum. Other cell lines used in this study were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) (Nissui Pharmaceutical Co. Ltd.) supplemented with 10% fetal bovine serum (HyClone Laboratories, Logan, UT, USA). Cells were grown and incubated in 5% CO 2 ± 95% air atmosphere at 378C in a humidi®ed atmosphere.
Assay for cell viability
Cells grown in DMEM supplemented with 10% fetal bovine serum were challenged with serial twofold dilutions of oxam¯atin on day 1 after the cells were seeded, and incubated for 2 days for the suspension cell cultures and for 3 days for the adherent cell cultures. Inhibition of the cell growth by oxam¯atin was determined by staining with MTT as described previously (Mosmann, 1983) .
Plasmid construction and transfection
A 1689 bp HindIII/XbaI fragment of the luciferase gene (luc+) derived from pGL3-Basic vector (Promega Co., Madison, WI, USA) was cloned into the pBK-CMV phagemid vector (CLONTECH Laboratories, Inc., Palo Alto, CA, USA) conferring neomycin resistance (pBCLuc). NIH3T3 cells (2610 5 ) grown in 35 mm dishes for 18 h were stably transfected with the CMV enhancer/ promoter-driven luciferase reporter vector pBC-Luc with the LipofectAmine reagent (Life Technologies, Inc. Grand Island, NY, USA) according to the manufacturer's instructions. Cells were cultured in the selective medium containing 400 mg/ml Geneticin (G418, Life Technologies, Inc.) 72 h after transfection. About 3 weeks later, colonies of the G418-resistant cells were isolated. One of the clones, named NCL-5, was found to express a high level of luciferase, of which activity was enhanced by TSA in a dose-dependent manner. NCL-5 cells were maintained in DMEM supplemented with 10% fetal bovine serum and 200 mg/ml Geneticin, and were used for determining the activity modulating the CMV promoter activity.
Luciferase assay
NCL-5 cells (1610 5 ) cultured in a 96-well multiwell plate for 6 h were incubated for 18 h in the medium containing various concentrations of drugs. The luciferase activity of each cell lysate was measured with a LucLite luciferase Reporter Gene Assay Kit (Packard Instrument Co., Meriden, CT, USA) and recorded with a Luminescencer-JNR luminometer (ATTO, Tokyo, Japan). Data were normalized to the protein concentration in cell lysates.
Analysis of DNA synthesis and the cell cycle DNA synthesis was measured by BrdU incorporation. A cell proliferation ELISA, BrdU (colorimetric) kit (Boehringer Mannheim, Germany) was used for detecting BrdU incorporation into cellular DNA. Brie¯y, HeLa cells (seeded in 96-well plates at a density of 1610 4 well and grown for 24 h) were treated with various concentrations of oxam¯atin for 24 h and then labeled with BrdU for 2 h. BrdU incorporated was detected with a peroxidaseconjugated anti-BrdU antibody and tetramethylbenzidine as a substrate, and was quanti®ed with a Spectra Max spectrometer (Molecular Devices Co., Sunnyvale, CA, USA).
To analyse the eects of oxam¯atin on the cell cycle progression, we determined the DNA content pro®le of a given population by¯ow cytometry according to the method described by Noguchi and Browne (1978) . Brie¯y, HeLa cells (1610 6 ) grown in 100-mm culture dishes were incubated for the indicated times with oxam¯atin. Cells were harvested by trypsinization and the nuclei were stained with propidium iodide. A FACSVantage (Becton Dickinson, San Jose, CA, USA)¯ow cytometer with a ModFit LT (Verity Software House, Inc., Topsham, ME, USA) software was used for analysis of the cell cycle phase distribution. Data were collected with at least 1610 4 cells.
RNA extraction and RT ± PCR analysis
HeLa cells (1610 6 ) grown in 100 mm culture dishes were incubated for 24 h with or without 1 mg/ml of oxam¯atin. Total RNA was extracted using TRIzol LS reagent (Life Technologies, Inc.). Endogenous gene expression was examined by PCR ampli®cation using speci®c primers and an RT ± PCR Kit (rTth DNA polymerase RT ± PCR high-Plus-, Toyobo, Tokyo, Japan). Primers for G3PDH, b-actin, and p53 were purchased from CLONTECH Laboratories, Inc. Primers synthesized were: 5-CAGAG-GAGGCGCCATGTCAG-3 and 5-CCTGTGGGCGGAT-TAGGG-3 for p21 WAF1/Cip1 , 5-TCAAACGTGCGAGTG-TCTAACG and 5-TTGGGGAACCGTCTGAAACAT-TTTC-3 for p27 Kip1 , 5-TTGCAGCAGTTGACCTAGAT-GAG-3 and 5-AACTGGAGTGTGTGGAGG-3 for Rb, 5-ATCTGCAGTATGACCTCCACTACTG-3 and 5-ATTG-GAGACCTTGTAGAGCTTGG-3 for gelsolin, 5-GGA-GAAGGTACCTATGGAGTTG-3 and 5-GCTACATCT-TCTTAATCTGATTGTCC-3 for Cdc2, 5-GGAGAACTT-CCAAAAGGTGG-3 and 5-CTGGCTTGGTCACATC-CTGG-3 for Cdk2, 5-TCTCGATATGAGCCAGTGGC-TG-3 and 5-TCCACGGGGCAGGGATACATC-3 for Cdk4, 5-ACTTGGATAAAGTTCCAGAGCCTGG-3 and 5-TGGGAAGGGCAACATCTCTAG-3 for Cdk6, 5-AC-CCCTTAAGGATCTTCCTG-3 and 5-TCCAGGGTATA-TCCAGTCTTTCG-3 for cyclin A, 5-TATCAGGG-CAAGCTGTGTTCC-3 and 5-ACTAAGAATGGTTGCC-ATCTC-3 for cyclin C, 5-GGATGCTGGAGGTCTGC-GAGGAAC-3 and 5-GAGAGGAAGCGTGTGAGGCG-GTAG-3 for cyclin D1, 5-ATCGAGGAGCGCTACCT-TCCGC-3 and 5-TTCCTCATCCTGCTGGAGC-3 for cyclin D2, and 5-ATTATTGCACCATCCAGAGGCTC-3 and 5-TGCGGCAGTAGCACTTCATGTAAGTC-3 for cyclin E. The conditions for PCR reactions were: cDNA synthesis at 608C for 30 min, pre-PCR denaturation at 948C for 2 min, denaturation at 948C for 1 min and annealing/extension 608C for 1 min 30 s for 40 cycles. Ampli®ed products were separated on a 2% agarose gel.
Western blot analysis
Cell lysates from HeLa cells treated with various concentrations of drugs were prepared by lyzing with brief sonication in IP buer (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM dithiothreitol, 0.1% Tween 20, 10% glycerol, 0.1 mM phenylmethylsulfonyl¯uoride, 60 mM 2-glycerophosphate, 1 mM NaF, 0.1 mM Na 3 VO 4 and 10 mM leupeptin, pH 6.8). Lyzed cells were centrifuged for 10 min at 48C, and the supernatants were frozen until analysis. Equal amounts of protein (30 mg protein/lane) were loaded and electrophoresed on SDS-polyacrylamide gels, and transferred onto an Immobilon-P membrane (Millipore Co, Bedford, MA, USA). After the membrane had been treated with an anti-human Jun D antibody (500 : 1 dilution, Clone 329, Sant Cruz Biotechnologies, Inc., Santa Cruz, CA, USA), an anti-human gelsolin antibody (1000 : 1 dilution, Clone 2, Transduction Laboratories, Inc., Lexington, KY, USA), an anti-human Cyclin A antibody (500 : 1 dilution, Clone BF683, Santa Cruz Biotechnologies, Inc.), an anti-human Cyclin D1 antibody (100 : 1 dilution, Clone 105, Transduction Laboratories Inc.), an anti-human Cyclin E antibody (500 : 1 dulution, Upstate Biotechnology, Lake Placid, NY, USA), an anti-human p21WAF1/Cip1 antibody (500 : 1 dilution, Clone 70, Transduction Laboratories Inc.), an anti-human p27Kip1 antibody (1000 : 1 dilution, Clone 57, Transduction Laboratories Inc.), an anti-human p16MTS1/ INK4A antibody (500 : 1 dilution, Clone F-12, Santa Cruz Biotechnologies, Inc), an anti-human p15MTS2/INK4B antibody (500 : 1 dilution, Clone K-18, Santa Cruz Biotechnologies, Inc.), an anti-human p18/INK4C antibody (500 : 1 dilution, Clone M-168, Santa Cruz Biotechnologies, Inc), an anti-human Cdc2 antibody (1000 : 1 dilution, Clone 17, Santa Cruz Biotechnologies, Inc.), an antihuman Cdk2 antibody (1000 : 1 dilution, Clone M-2, Santa Cruz Biotechnologies, Inc.), an anti-human Cdk4-antibody (1000 : 1 dilution, Clone H-303, Santa Cruz Biotechnologies, Inc.), or an anti-human Cdk6 antibody (1000 : 1 dilution, Clone C-21, Santa Cruz Biotechnologies, Inc.), the immune complexes were detected with ECL Western blotting detection reagents (Amersham Life Science). Western blotting with an anti-human pRb antibody (Oncogene Research Products, Cambridge, MA, USA) following immunoprecipitation with the same antibody (500 : 1 dilution) was used for the immunodetection of Rb.
Extraction of histones and acid urea Triton gel electrophoresis
Histones of cultured cells were extracted as described previously . HeLa cells (1610 6 cells) treated with or without drugs for 12 h were collected and lyzed in 1 ml of ice-cold lysis buer (10 mM Tris-HCl, 50 mM sodium bisul®te, 1% Triton X-100, 10 mM MgCl 2 , 8.6% sucrose, pH 6.5) by Dounce homogenization. Nuclei were collected by centrifugation, washed three times with the lysis buer and once with 10 mM Tris-HCl, 13 mM EDTA, pH 7.4, successively. After centrifugation, the nuclear pellet was suspended in 0.1 ml of ice-cold H 2 O and then concentrated H 2 SO 4 was added to the suspension to give a concentration of 0.4 N. After incubation at 48C for 1 h, the suspension was centrifuged and the supernatant was taken and mixed with 1 ml of acetone. The coagulated material, obtained after overnight incubation at 7208C, was collected and air-dried. The acid soluble histone fraction was dissolved in 50 ml of H 2 O. The level of histone acetylation was analysed by slab gel electrophoresis using an acid/urea/Triton (AUT) gel (1 M acetic acid, 8 M urea, 0.5% Triton X-100, 45 mM NH 3 , 16% acrylamide) with an upper gel (1 M acetic acid, 6.3 M urea, 4.4% acrylamide). After the extracted histones had been mixed with loading buer (7.4 M urea, 1.4 M NH 3 , 10 mM dithiothreitol), electrophoresis was performed in 0.2 M glycine, 1 M acetic acid and then the gels were stained with Coomassie Brilliant Blue R-250 (Nacalai tesque).
Partial puri®cation and assay of HDAC
Partial puri®cation of HDAC and preparation of [ 3 H]acetylated histones were carried out as described . The assay for in vitro deacetylation of histones was done basically according to that proposed by Inoue and Fujimoto (1970) . The partially puri®ed enzyme fraction was preincubated with various inhibitors for 5 min prior to the enzyme reaction. For the standard assay, 6 ml of 3 H-acetyl-labeled histones (2500 c.p.m./5 mg) was added to 94 ml of the enzyme fraction and the mixture was incubated at 378C for 15 min. The enzyme reaction is linear for at least 1 h under these conditions. The reaction was stopped by the addition of 10 ml of concentrated HCl. The released [ 3 H]acetic acid was extracted with 1 ml of ethylacetate and 0.9 ml of the solvent layer was taken into 5 ml of ACS (aqueous counting scintillant) II solution (Amersham Life Science) for determination of radioactivity.
In vivo antitumor activity BDF1 mice (female, 6 weeks old) used in this study were produced in the breeding colony and maintained in a SPF facility at Aburahi Laboratory (Shionogi Co., Ltd., Tokyo). B16 murine melanoma was provided by D Kasuga (Tokyo Med. and Dent. Univ.) and was maintained by serial subcutaneous transplantation as tumor fragments in C57BL/6. Oxam¯atin, suspended in the vehicle (saline including 0.4% Tween 80, 0.5% carboxymethylcellulose and 0.9% benzylalcohol), was injected intraperitoneally into BDF1 mice on day 1, 3, 5, 7, 9 and 11 and after the intraperitoneal inoculation of single cell suspension of the B16 melanoma cells (10 6 cells). The survival days of the animals were recorded and the percent of increased life span (ILS%) was calculated. All studies were performed with the approval of Shionogi Animal Care and Use Committee.
